AACT advocates for the safe deployment of cellular therapies within informed regulatory oversight.
AACT’s diverse membership works to increase public awareness and facilitate increased patient access to regenerative medicine.
Chairman of the AACT Executive Board, Dr. Leslie Miller, Speaks at FDA Public Hearing
Excerpt. . . Read Full Presentation HERE
Importantly, we believe that such a Registry could address most of the valid criticisms and concerns about the current unrestricted use of cell therapy.In order to participate, a clinic would have to meet the following rigorous criteria:
1. TO ADDRESS CONCERNS ABOUT INCOMPLETE DATA: Agree to enroll every patient treated for every indication and provide de-identified data on indication, symptoms, demographics, etc.
2. TO ADDRESS THE VARIABLE QUALITY OF CELLS DELIVERED: Must obtain certification of cell preparation lab either on site or the vendor, with complete data on source, prep, type and number, quality and route of delivery.